Review



human breast cancer tissue array  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Novus Biologicals human breast cancer tissue array
    Human Breast Cancer Tissue Array, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer tissue array/product/Novus Biologicals
    Average 93 stars, based on 20 article reviews
    human breast cancer tissue array - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    94
    MedChemExpress biological samples breast tumor tissues
    Biological Samples Breast Tumor Tissues, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/biological samples breast tumor tissues/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    biological samples breast tumor tissues - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    96
    AMS Biotechnology er pr
    Er Pr, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/er pr/product/AMS Biotechnology
    Average 96 stars, based on 1 article reviews
    er pr - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    86
    Anhui Medical University human breast cancer tissue
    ARTS is predominantly expressed in resistant <t>breast</t> <t>cancer</t> <t>tissues</t> and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.
    Human Breast Cancer Tissue, supplied by Anhui Medical University, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer tissue/product/Anhui Medical University
    Average 86 stars, based on 1 article reviews
    human breast cancer tissue - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    93
    Novus Biologicals human breast cancer tissue array
    ARTS is predominantly expressed in resistant <t>breast</t> <t>cancer</t> <t>tissues</t> and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.
    Human Breast Cancer Tissue Array, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer tissue array/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    human breast cancer tissue array - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    86
    Human Protein Atlas breast cancer tissue
    ARTS is predominantly expressed in resistant <t>breast</t> <t>cancer</t> <t>tissues</t> and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.
    Breast Cancer Tissue, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer tissue/product/Human Protein Atlas
    Average 86 stars, based on 1 article reviews
    breast cancer tissue - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC breast cancer tissues bc08118b
    ARTS is predominantly expressed in resistant <t>breast</t> <t>cancer</t> <t>tissues</t> and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.
    Breast Cancer Tissues Bc08118b, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer tissues bc08118b/product/TissueArray.com LLC
    Average 90 stars, based on 1 article reviews
    breast cancer tissues bc08118b - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC breast cancer tissue microarray bc08118b
    ARTS is predominantly expressed in resistant <t>breast</t> <t>cancer</t> <t>tissues</t> and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.
    Breast Cancer Tissue Microarray Bc08118b, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer tissue microarray bc08118b/product/TissueArray.com LLC
    Average 90 stars, based on 1 article reviews
    breast cancer tissue microarray bc08118b - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Human Protein Atlas bcl6 in breast cancer tissue
    ARTS is predominantly expressed in resistant <t>breast</t> <t>cancer</t> <t>tissues</t> and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.
    Bcl6 In Breast Cancer Tissue, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcl6 in breast cancer tissue/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    bcl6 in breast cancer tissue - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    96
    AMS Biotechnology br1202b breast cancer tissue array
    ELISA analysis of sulfatases and SULF2 immunohistochemistry. ELISAs were performed to examine the basal levels of (a) SULF1 and (b) SULF2 in adjusted cell supernatants inversely proportionate to the protein concentration in the corresponding cell lysate of MCF-10A cell line, TNBC MDA-MB 231, Hs 578t and MDA-MB 468 cell lines and ER+/PR+ T47D, MCF-7 and ZR-75-1 cell lines. MCF-10A expressed more SULF1 in comparison to the TNBCs but similar expression levels were observed in ER+/PR+ T47D and MCF-7 cells. However, the ER+/PR+ ZR-75-1 cell line expressed the most SULF1. Meanwhile, TNBCs and ER+/PR+ T47D and ZR-75-1 cells expressed more SULF2 in comparison to MCF-10A cells. Standard deviation was calculated from three independent experiments performed in triplicate. The student’s t-test was performed to determine significance with *representing p < 0.05 and **representing p < 0.01 comparing the protein expression MCF-10A to the protein expressions of TNBC cell lines. (b) The AMSBIO <t>BR1202B</t> breast cancer tissue array (120 cores with 82 TNBC cores, 20 ER+/PR+ cores, 14 <t>HER2+</t> cores, and 4 necrotic cores; key can be found in supplemental Figure <t>S6C)</t> was stained with SULF2.
    Br1202b Breast Cancer Tissue Array, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/br1202b breast cancer tissue array/product/AMS Biotechnology
    Average 96 stars, based on 1 article reviews
    br1202b breast cancer tissue array - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    Image Search Results


    ARTS is predominantly expressed in resistant breast cancer tissues and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.

    Journal: Research

    Article Title: ARTS Confers Chemoresistance of Breast Cancer by Inducing Apoptosis-Dependent Autophagy via Livin–MDM2–p53 Pathway

    doi: 10.34133/research.1086

    Figure Lengend Snippet: ARTS is predominantly expressed in resistant breast cancer tissues and promotes chemoresistance in breast cancer cells. (A) Screening workflow for chemoresistance-related genes in breast cancer. DEGs from GSE288073 are shown in a volcano plot, followed by overlap with apoptosis-related and mitochondria-related gene sets, yielding 12 DEGs; ARTS was prioritized and evaluated by Kaplan–Meier survival analysis for postchemotherapy prognosis. FPKM, fragments per kilobase of transcript per million mapped reads. (B) Representative hematoxylin and eosin (H&E) and IHC images of ARTS in paired pre- and post-NAC samples from NAC-sensitive and NAC-resistant patients. The black arrow indicates a residual small cluster of tumor cells. Scale bar, 50 μm. (C) Association of ARTS protein with MPG score and Ki-67 in pre- and post-NAC samples. (D) Kaplan–Meier analyses of OS and RFS stratified by ARTS protein (low versus high). (E and F) MTT and (G and H) colony formation assays in sh-Ctrl versus sh-ARTS MDA-MB-231 and Flag versus Flag–ARTS MCF-7 cells under the indicated treatments. * P < 0.05; *** P < 0.001. ns, not significant.

    Article Snippet: Human breast cancer tissue samples were obtained from the First Affiliated Hospital of Anhui Medical University (Hefei, Anhui, China).

    Techniques:

    ELISA analysis of sulfatases and SULF2 immunohistochemistry. ELISAs were performed to examine the basal levels of (a) SULF1 and (b) SULF2 in adjusted cell supernatants inversely proportionate to the protein concentration in the corresponding cell lysate of MCF-10A cell line, TNBC MDA-MB 231, Hs 578t and MDA-MB 468 cell lines and ER+/PR+ T47D, MCF-7 and ZR-75-1 cell lines. MCF-10A expressed more SULF1 in comparison to the TNBCs but similar expression levels were observed in ER+/PR+ T47D and MCF-7 cells. However, the ER+/PR+ ZR-75-1 cell line expressed the most SULF1. Meanwhile, TNBCs and ER+/PR+ T47D and ZR-75-1 cells expressed more SULF2 in comparison to MCF-10A cells. Standard deviation was calculated from three independent experiments performed in triplicate. The student’s t-test was performed to determine significance with *representing p < 0.05 and **representing p < 0.01 comparing the protein expression MCF-10A to the protein expressions of TNBC cell lines. (b) The AMSBIO BR1202B breast cancer tissue array (120 cores with 82 TNBC cores, 20 ER+/PR+ cores, 14 HER2+ cores, and 4 necrotic cores; key can be found in supplemental Figure S6C) was stained with SULF2.

    Journal: Cancer Biology & Therapy

    Article Title: Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP

    doi: 10.1080/15384047.2025.2483989

    Figure Lengend Snippet: ELISA analysis of sulfatases and SULF2 immunohistochemistry. ELISAs were performed to examine the basal levels of (a) SULF1 and (b) SULF2 in adjusted cell supernatants inversely proportionate to the protein concentration in the corresponding cell lysate of MCF-10A cell line, TNBC MDA-MB 231, Hs 578t and MDA-MB 468 cell lines and ER+/PR+ T47D, MCF-7 and ZR-75-1 cell lines. MCF-10A expressed more SULF1 in comparison to the TNBCs but similar expression levels were observed in ER+/PR+ T47D and MCF-7 cells. However, the ER+/PR+ ZR-75-1 cell line expressed the most SULF1. Meanwhile, TNBCs and ER+/PR+ T47D and ZR-75-1 cells expressed more SULF2 in comparison to MCF-10A cells. Standard deviation was calculated from three independent experiments performed in triplicate. The student’s t-test was performed to determine significance with *representing p < 0.05 and **representing p < 0.01 comparing the protein expression MCF-10A to the protein expressions of TNBC cell lines. (b) The AMSBIO BR1202B breast cancer tissue array (120 cores with 82 TNBC cores, 20 ER+/PR+ cores, 14 HER2+ cores, and 4 necrotic cores; key can be found in supplemental Figure S6C) was stained with SULF2.

    Article Snippet: The student’s t-test was performed to determine significance with *representing p < 0.05 and **representing p < 0.01 comparing the protein expression MCF-10A to the protein expressions of TNBC cell lines. (b) The AMSBIO BR1202B breast cancer tissue array (120 cores with 82 TNBC cores, 20 ER+/PR+ cores, 14 HER2+ cores, and 4 necrotic cores; key can be found in supplemental Figure S6C) was stained with SULF2.

    Techniques: Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Protein Concentration, Comparison, Expressing, Standard Deviation, Staining

    Statistical analysis for SULF2 immunohistochemistry. For the breast cancer tissue array and slides stained for heparanase: TNBC ( n =75), ER+/PR+ ( n =18), HER2+ ( n =14), (a) images were taken of SULF2-stained AMSBIO BR1202B breast cancer tissue array on an evos FL auto 2 microscope (40×). (b) Pairwise comparisons using Dunn’s test indicated that there was a significant difference in H-score between breast cancer sub-types TNBC and ER+/PR+ ( p = 0.0392). There was no significant different between TNBC and HER2+. (c) The Kruskal-Wallis test indicated that there was no significant difference in the average percentages of cells that stained positively for SULF2 in tissue sections of TNBC, ER+/PR+ breast cancer, and HER2+ breast cancer. (d) Pairwise comparisons using Dunn’s test indicated that there was a significant difference between breast cancer sub-types TNBC and ER+/PR+ ( p = 0.009), and TNBC and HER2+ ( p = 0.0338), in the percentages of cells that stained moderately or strongly positive for SULF2. (e) The same Dunn’s test from (d) also indicated that there was a significant difference between cancer sub-types TNBC and ER+/PR+ ( p = 0.0094), and TNBC and HER2+( p = 0.0338), in the percentages of cells that stained negative or weakly positive for SULF2. (f) Pairwise comparisons using Dunn’s test showed that there was a significant difference between TNBC breast cancer stages 2A and 2B ( p = 0.0007) in the percentages of cells that stained positively for SULF2. No other differences among different TNBC stages were significant. Standard error of the mean was calculated. For statistical analysis, *representing p < 0.05, **representing p < 0.01 and ***representing p < 0.001.

    Journal: Cancer Biology & Therapy

    Article Title: Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP

    doi: 10.1080/15384047.2025.2483989

    Figure Lengend Snippet: Statistical analysis for SULF2 immunohistochemistry. For the breast cancer tissue array and slides stained for heparanase: TNBC ( n =75), ER+/PR+ ( n =18), HER2+ ( n =14), (a) images were taken of SULF2-stained AMSBIO BR1202B breast cancer tissue array on an evos FL auto 2 microscope (40×). (b) Pairwise comparisons using Dunn’s test indicated that there was a significant difference in H-score between breast cancer sub-types TNBC and ER+/PR+ ( p = 0.0392). There was no significant different between TNBC and HER2+. (c) The Kruskal-Wallis test indicated that there was no significant difference in the average percentages of cells that stained positively for SULF2 in tissue sections of TNBC, ER+/PR+ breast cancer, and HER2+ breast cancer. (d) Pairwise comparisons using Dunn’s test indicated that there was a significant difference between breast cancer sub-types TNBC and ER+/PR+ ( p = 0.009), and TNBC and HER2+ ( p = 0.0338), in the percentages of cells that stained moderately or strongly positive for SULF2. (e) The same Dunn’s test from (d) also indicated that there was a significant difference between cancer sub-types TNBC and ER+/PR+ ( p = 0.0094), and TNBC and HER2+( p = 0.0338), in the percentages of cells that stained negative or weakly positive for SULF2. (f) Pairwise comparisons using Dunn’s test showed that there was a significant difference between TNBC breast cancer stages 2A and 2B ( p = 0.0007) in the percentages of cells that stained positively for SULF2. No other differences among different TNBC stages were significant. Standard error of the mean was calculated. For statistical analysis, *representing p < 0.05, **representing p < 0.01 and ***representing p < 0.001.

    Article Snippet: The student’s t-test was performed to determine significance with *representing p < 0.05 and **representing p < 0.01 comparing the protein expression MCF-10A to the protein expressions of TNBC cell lines. (b) The AMSBIO BR1202B breast cancer tissue array (120 cores with 82 TNBC cores, 20 ER+/PR+ cores, 14 HER2+ cores, and 4 necrotic cores; key can be found in supplemental Figure S6C) was stained with SULF2.

    Techniques: Immunohistochemistry, Staining, Microscopy